Medivir to Showcase Phase 2 Advances for Key Cancer and Bone Disease Programs

Medivir AB ( (SE:MVIR) ) just unveiled an announcement.

Medivir AB, a Swedish pharmaceutical developer focused on high unmet medical needs, is advancing two key clinical programs: fostrox for primary liver cancer and MIV-711 for Osteogenesis Imperfecta. The company leverages a partnership-driven model alongside in-house development and is listed on the Small Cap segment of Nasdaq Stockholm.

The company will present at the DNB/Carnegie Healthcare Seminar 2026 on March 9, where CEO Jens Lindberg will outline progress as Medivir launches phase 2 development of MIV-711 in a new strategic indication and continues phase 2 work on fostrox in primary liver cancer. Bolstered by a recent rights issue and a directed share issue to Carl Bennet AB, Medivir underscores the blockbuster potential of both candidates and the prospect of becoming first approved treatments in their respective patient populations, signaling heightened expectations for future value creation and industry positioning.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Swedish pharmaceutical company listed on Nasdaq Stockholm’s Small Cap segment, specializing in innovative therapies for diseases with high unmet medical need. Its lead programs include fostrox, a precision chemotherapy targeting liver cancer cells while limiting side effects, and MIV-711, a treatment candidate for Osteogenesis Imperfecta, both positioned as potential blockbuster drugs that could significantly benefit patients and shareholders.

Average Trading Volume: 6,578,980

Technical Sentiment Signal: Sell

Current Market Cap: SEK770.3M

See more data about MVIR stock on TipRanks’ Stock Analysis page.